Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSVCBD Injection in Autoimmune Diseases
NCT07613411Phase 1Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 6 more, sponsored by Chinese PLA General Hospital. Primary endpoints: Dose limited toxicity at 28 days, Adverse events and serious adverse events at 24 months and 2 more. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathy (IIM)Sjögren's syndrome
Beyond the preview
Go deeper on NCT07613411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613411.